Angiogenesis and radiotherapy (vessels, anaemia, oxygen and radiosensitivity);Angiogenèse et radiothérapie (vaisseaux, anémie, oxygène et radiosensibilité)

Bulletin du Cancer

Volumn 94, Issue SPECIAL, 2007, Pages

  Lartigau, Éric ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Angiogenesis; Hypoxia; Radiotherapy; Vascularisation

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANEMIA; ANGIOGENESIS; CANCER GROWTH; CANCER RADIOTHERAPY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HYPOXIA; IONIZING RADIATION; OXYGEN BLOOD LEVEL; RADIOSENSITIVITY; REVIEW;

ANEMIA; ANGIOGENESIS INHIBITORS; ANIMALS; CELL HYPOXIA; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; OXYGEN CONSUMPTION; PARTIAL PRESSURE; RADIATION TOLERANCE;

EID: 34548639942     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0351     Document Type: Review

References (61)

1. Raleigh J, Dewhirst M, Thrall D. Measuring tumor hypoxia. Semin Radiat Oncol 1996 ; 46 : 229-37.
2. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and possible implications for radiotherapy. Br J Cancer 1955 ; 9 : 539.
3. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953 ; 26 : 638-48.
4. Brizel D, Sibley G, Prosnitz L, Sher R, Dewhirst M. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997 ; 38 : 285-9.
5. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998 ; 48 : 149-56.
6. Horsman M. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998 ; 42 : 701-4.
7. Lartigau E, Le Ridant AM, Lambin P, Weeger P, Martin L, Sigal R, et al. Oxygenation of head and neck tumors. Cancer 1993 ; 71 : 2319-25.
8. Höckel M, Schlenger K, Mitze M, Schaeffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 1996 ; 6 : 3-9.
9. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996 ; 41 : 31-9.
10. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996 ; 16 : 4604-13.
11. Maxwell P, Dachs GU, Gleadle J, Gleadle J. Hypoxia inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proc Natl Acad Sci USA 1997 ; 94 : 8104-9.
12. Hasan NM, Adams GE, Joiner MC, Marshall JF, Hart IR. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer 1998 ; 77 : 1799-805.
13. Graeber T, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996 ; 379 : 88-91.
14. Teicher BA, Holden SA, Al-Achi A, et al. Classification of antineoplasic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990 ; 50 : 3339-44.
15. Dubray B, Mosseri V, Brunin F, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer : a prospective study. Radiology 1996 ; 201 : 553-8.
16. Lee R, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma : a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998 ; 5 : 1069-75.
17. Warde P, OSullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy : the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998 ; 41 : 347-53.
18. Becker A, Stadler P, Lavey RS, et al. Severe anaemia is associated with poor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000 ; 46 : 459-66.
19. Churchill-Davidson I, Sanger C, Thomlinson RH. High pressure oxygen and radiotherapy. Lancet 1955 ; 1 : 1091-5.
20. Dische S, Saunders MI, Sealy R, et al. Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy : a report of a randomised controlled trial. Radiother Oncol 1999 ; 53 : 93-8.
21. Pasquier D, Lartigau E. Anémie et radiothérapie. Bull Cancer 2003 ; 90 : S152-7.
22. Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M, Wara W, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy : final report of a randomized, open- labelled, phase II trial. Br J Cancer 1998 ; 77 : 1996-2002.
23. Antonadou D, Cardamakis E, Sarris G, Tzigounis V, Throuvalas V. Effect of the administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy. Radiother Oncol 1998 ; S48 : 483.
24. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy : randomised, double blind, placebo-controlled trial. Lancet 2003 ; 362 : 1255-60.
25. Acs G, Zhang PJ, Rebbeck TR, et al. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002 ; 95 : 969-81.
26. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998 ; 46 : 135-46.
27. Horsman MR, Bohm L, Margison GP, Milas L, Rosier JF, Safrany G, et al. Tumor radiosensitizers : current status of development of various approaches : report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys 2006 ; 64 : 551-61.
28. Nieder C, Wiedenmann N, Andratschke N, Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006 ; 32 : 348-64.
29. Folkamn J. Tumor angiogenesis : therapeutic implications. N Engl J Med 1971 ; 21 : 1182-6.
30. Deutsch E, Kaliski A, Maggiorella L, Bourhis J. New strategies to interfere with radiation response : "biomodulation" of radiation therapy. Cancer Radiother 2005 ; 9 : 69-76.
31. Hennequin C, Giocanti N, Favaudon V. Targeted therapies and radiotherapy. Bull Cancer 2005 ; 92 : 1085-92.
32. Tsai JH, Makonnen S, Feldman M, et al. Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biol Ther 2005 ; 4 : 1395-400.
33. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003 ; 5622 : 1155-9.
34. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 2006 ; 16 : 45-50.
35. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003 ; 57 : 1047-55.
36. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002 ; 53 : 164-71.
37. Gupta VK, Jaskowiak NT, Beckett MA, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002 ; 8 : 47-54.
38. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999 ; 59 : 3374-8.
39. Li J, Huang S, Armstrong EA, et al. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 2005 ; 62 : 1477-85.
40. Hansen-Algenstaedt N, Stoll BR, Padera TP, Dolmans DE, Hicklin DJ, Fukumura D, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000 ; 45 : 56-60.
41. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998 ; 58 : 5686-9.
42. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy : schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004 ; 10 : 8587-93.
43. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992 ; 52 : 6702-4.
44. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998 ; 394 : 287-91.
45. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001 ; 61 : 39-44.
46. Zips D, Hessel F, Krause M, Schiefer Y, Hoinkis C, Thames HD, et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 2005 ; 61 : 908-14.
47. Brazelle WD, Shi W, Siemann DW. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys 2006 ; 65 : 836-41.
48. Fuks Z, Persaud RS, Alfieri A, McLoughlin M, Ehleiter D, Schwartz JL, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994 ; 54 : 2582-90.
49. Hitt R, Martin P, Hidalgo M. Cetuximab in squamous cell carcinoma of the head and neck. Future Oncol 2006 ; 2 : 449-57.
50. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head an neck. N Engl J Med 2006 ; 354 : 567-78.
51. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 anti epidermal growth factor receptor antibody. Clin Cancer Res 2000 ; 6 : 701-8.
52. Huang S, Harari P. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinoma : inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res 2000 ; 6: 2166-74.
53. Suit HD, Sedlacek RS, Gillette EL. Examination for a correlation between probabilities of development of distant metastasis and of local recurrence. Radiology 1970 ; 95 : 189-94.
54. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001 ; 61 : 2207-11.
55. Milas L. Tumor bed effect in murine tumors : relationship to tumor take and tumor macrophage content. Radiat Res 1990 ; 123 : 232-6.
56. Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 1997 ; 37 : 1107-13.
57. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000 ; 60 : 5565-70.
58. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005 ; 11 : 743-50.
59. Levin VA, Phuphanich S, Yung WK, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006 ; 78 : 295-302.
60. Citrin D, Menard C, Camphausen K. Combining radiotherapy and angiogenesis inhibitors : clinical trial design. Int J Radiat Oncol Biol Phys 2006 ; 64 : 15-25.
61. Hennequin C, Giocanti N, Favaudon V. Thérapies ciblées et radiothérapie. Bull Cancer 2005 ; 92 : 1085-92.